Stay updated on Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.3%
- Check8 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference4%
- Check15 days agoChange DetectedThe page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest has been deleted.SummaryDifference5%
- Check23 days agoChange DetectedThe date has been updated from April 17, 2025, to June 24, 2025.SummaryDifference0.6%
- Check30 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference4%
- Check44 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.3%
Stay in the know with updates to Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.